Skip to content
value.today

Jounce Therapeutics, Inc.

Total raised
$91 M
2 rounds on record
Latest round
$35 M
Oct 2020
First round on record
Apr 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Jounce Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$35 MNo. 2$10 to $50 million

Jounce Therapeutics, Inc.: Raise no. 2, Oct 2020

Investors in this round

1 investor had bought by the notice of Oct 29, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Jounce Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth G. Trehu · Executive Officer
  • Hugh M. Cole · Executive Officer
  • Kimberlee C. Drapkin · Executive Officer
  • Richard Murray · Executive Officer, Director
  • Barbara G. Duncan · Director
  • Cary G. Pfeffer · Director
  • Duncan G. Higgons · Director
  • Luis A. G. Diaz, Jr. · Director
  • Perry G. Karsen · Director
  • Robert G. Iannone · Director
  • Robert G. Kamen · Director
  • Robert G. Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kim C. Drapkin, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 29, 2020. Read the notice at the SEC.

equitySEC
Apr 2015$56 MNo. 1$50 to $250 million

Jounce Therapeutics, Inc.: Raise no. 1, Apr 2015

Investors in this round

14 investors had bought by the notice of Apr 29, 2015: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Jounce Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anna L. Barry · Executive Officer
  • Kim C. Drapkin · Executive Officer
  • Richard Murray · Executive Officer, Director
  • Cary G. Pfeffer · Director
  • Robert G. Kamen · Director
  • Robert G. Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold shown in item 13 and number of investors shown in item 14 include $10,000,000 from 2 non-US investors.”

Signed by Anna L. Barry, VP of Legal & Secretary. Source: SEC Form D, newest notice filed Apr 29, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Jounce Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2020).

    SEC Form D · Oct 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2020

That is all the official record says: Jounce Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website did not answer.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Jounce Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Celgene Corp /de/Companynot statednot statedHeld Series B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Celgene Switzerland LLCOthernot statednot statedHeld Series B-1 preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures GP II, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Rock Ventures II, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
TRV GP II, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Jounce Therapeutics, Inc.
NameRoleNamed in
Elizabeth G. TrehuExecutive officerOct 2020
Hugh M. ColeExecutive officerOct 2020
Kimberlee C. DrapkinExecutive officerOct 2020
Richard MurrayExecutive officerOct 2020
Anna L. BarryExecutive officerApr 2015
Kim C. DrapkinExecutive officerApr 2015
Barbara G. DuncanDirectorOct 2020
Cary G. PfefferDirectorOct 2020
Duncan G. HiggonsDirectorOct 2020
Luis A. G. Diaz, Jr.DirectorOct 2020
Perry G. KarsenDirectorOct 2020
Richard MurrayDirectorOct 2020
Robert G. IannoneDirectorOct 2020
Robert G. KamenDirectorOct 2020
Robert G. TepperDirectorOct 2020

About

Company.